[go: up one dir, main page]

MA32798B1 - Acides naphtylacétiques - Google Patents

Acides naphtylacétiques

Info

Publication number
MA32798B1
MA32798B1 MA33847A MA33847A MA32798B1 MA 32798 B1 MA32798 B1 MA 32798B1 MA 33847 A MA33847 A MA 33847A MA 33847 A MA33847 A MA 33847A MA 32798 B1 MA32798 B1 MA 32798B1
Authority
MA
Morocco
Prior art keywords
compounds
formula
naftilacetic
acids
invention concerns
Prior art date
Application number
MA33847A
Other languages
Arabic (ar)
English (en)
Inventor
Fariborz Firooznia
Paul Gillespie
Yun He
Li Chen
Tai-An Lin
Eric Mertz
Sung-Sau So
Hongying Yun
Zhenshan Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA32798B1 publication Critical patent/MA32798B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE LES COMPOSÉS DE FORMULE I, AINSI QUE LEURS SELS ET ESTERS DE QUALITÉ PHARMACEUTIQUE, OÙ W, X, Y ET R1-R7 SONT TELS QUE DÉFINIS DANS LA DESCRIPTION DÉTAILLÉE ET DANS LES REVENDICATIONS. DE PLUS, LA PRÉSENTE INVENTION CONCERNE DES MÉTHODES DE FABRICATION ET D'EMPLOI DES COMPOSÉS DE FORMULE I AINSI QUE DES COMPOSITIONS PHARMACEUTIQUES CONTENANT DE TELS COMPOSÉS. LES COMPOSÉS DE FORMULE I SONT DES ANTAGONISTES OU DES AGONISTES PARTIELS DU RÉCEPTEUR CRTH2 ET PEUVENT ÊTRE EMPLOYÉS DANS LE TRAITEMENT DE PATHOLOGIES ET DE TROUBLES ASSOCIÉS À CE RÉCEPTEUR, COMME L'ASTHME.
MA33847A 2008-11-17 2011-05-16 Acides naphtylacétiques MA32798B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11513308P 2008-11-17 2008-11-17
US22218209P 2009-07-01 2009-07-01
PCT/EP2009/064810 WO2010055004A1 (fr) 2008-11-17 2009-11-09 Acides naphtylacétiques

Publications (1)

Publication Number Publication Date
MA32798B1 true MA32798B1 (fr) 2011-11-01

Family

ID=41467025

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33847A MA32798B1 (fr) 2008-11-17 2011-05-16 Acides naphtylacétiques

Country Status (29)

Country Link
US (1) US8642629B2 (fr)
EP (1) EP2346819B1 (fr)
JP (1) JP5463365B2 (fr)
KR (1) KR101322496B1 (fr)
CN (1) CN102216265B (fr)
AR (1) AR074352A1 (fr)
AU (1) AU2009315712A1 (fr)
BR (1) BRPI0921038A2 (fr)
CA (1) CA2740863A1 (fr)
CO (1) CO6351778A2 (fr)
CR (1) CR20110219A (fr)
CY (1) CY1114200T1 (fr)
DK (1) DK2346819T3 (fr)
EC (1) ECSP11011057A (fr)
ES (1) ES2408963T3 (fr)
HR (1) HRP20130613T1 (fr)
IL (1) IL212077A0 (fr)
MA (1) MA32798B1 (fr)
MX (1) MX2011005120A (fr)
NZ (1) NZ591914A (fr)
PE (1) PE20110703A1 (fr)
PL (1) PL2346819T3 (fr)
PT (1) PT2346819E (fr)
RS (1) RS52809B (fr)
RU (1) RU2539185C2 (fr)
SG (1) SG171734A1 (fr)
TW (1) TWI377197B (fr)
WO (1) WO2010055004A1 (fr)
ZA (1) ZA201102524B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006944A1 (fr) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Acides aminotétrahydroindazoloacétiques
JP5394487B2 (ja) 2008-07-15 2014-01-22 エフ．ホフマン−ラ ロシュ アーゲー アミノテトラヒドロインダゾロ酢酸
CA2739725A1 (fr) * 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Acides naphtylacetiques employes en tant qu'antagonistes ou agonistes partiels de crth2
CN102216249A (zh) 2008-11-17 2011-10-12 霍夫曼-拉罗奇有限公司 萘乙酸
AU2011275417A1 (en) 2010-07-05 2013-02-21 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
US8470884B2 (en) * 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
US8691993B2 (en) * 2011-12-12 2014-04-08 Hoffmann-La Roche Inc. Piperidinyl naphthylacetic acids
TW201331179A (zh) 2011-12-21 2013-08-01 Actelion Pharmaceuticals Ltd 雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途
US9000044B2 (en) 2012-02-28 2015-04-07 Hoffmann-La Roche Inc. Substituted naphthylacetic acids
CA2876808A1 (fr) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd Derives heterocyclyles 1-phenyl-substitues et leur utilisation en tant que modulateurs du recepteur de la prostaglandine d2
CN108040481B (zh) 2015-04-24 2020-10-30 先正达参股股份有限公司 具有硫取代的五元环杂环的杀有害生物活性多环衍生物
WO2018129529A1 (fr) 2017-01-09 2018-07-12 The Children's Hospital Of Philadelphia Compositions et méthodes ciblant la voie th2 pour le traitement de l'asthme
AR128577A1 (es) * 2022-03-01 2024-05-22 Syngenta Crop Protection Ag Compuestos herbicidas

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899529A (en) 1973-02-22 1975-08-12 Merck & Co Inc Aroyl substituted naphthalene acetic acids
US4443462A (en) 1979-08-06 1984-04-17 Merrell Dow Pharmaceuticals Inc. Antipsychotic 4-(naphthalenyloxy)piperidine derivatives
US4371537A (en) 1981-08-13 1983-02-01 The Dow Chemical Company Sulfur-substituted phenoxypyridines having antiviral activity
DE3631824A1 (de) 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
DE3623941A1 (de) 1986-07-16 1988-01-28 Bayer Ag Substituierte amino-5,6,7,8-tetrahydronaphthyl-oxyessigsaeuren, verfahren zu deren herstellung sowie die verwendung als arzneimittel
EP0405602A1 (fr) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. Dérivés zinciques de substances antiiflammatoires doués d'une activité thérapeutique améliorée
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
DE4235155A1 (de) 1992-10-19 1994-04-21 Basf Ag Verfahren zur Herstellung von Methylsulfonylbenzoesäuren
JP2562405B2 (ja) 1993-04-06 1996-12-11 花王株式会社 ケラチン繊維処理剤組成物
DE69410956T2 (de) 1993-12-09 1999-03-25 Ono Pharmaceutical Co. Ltd., Osaka Naphthylessigsäurederivate als PGEZ Agonisten und Antagonisten
GB9516788D0 (en) 1995-08-16 1995-10-18 Agrevo Uk Ltd Fungicides
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
GB0028702D0 (en) * 2000-11-24 2001-01-10 Novartis Ag Organic compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
EP2423190A1 (fr) 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Composés présentant un antagonisme du récepteur PGD 2
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
NZ541234A (en) * 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
US20070161698A1 (en) 2003-05-30 2007-07-12 Microbia, Inc. Modulators of CRTH2 Activity
RU2006101541A (ru) 2003-06-20 2006-06-10 Амген Инк. (US) Производные пиперазина и способ их применения
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
BRPI0415437A (pt) 2003-10-14 2006-12-05 Oxagen Ltd composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7226951B2 (en) 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
JP2008513511A (ja) 2004-09-21 2008-05-01 アサーシス， インク． Ｃｒｔｈ２受容体拮抗作用を示すベンズイミダゾール酢酸およびこれらの使用
AU2005289881A1 (en) 2004-09-23 2006-04-06 Amgen Inc. Substituted sulfonamidopropionamides and methods of use
WO2006032466A2 (fr) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd Nouveaux antibiotiques bicycliques
CN101111472A (zh) 2004-12-21 2008-01-23 弗·哈夫曼-拉罗切有限公司 1,2,3,4-四氢化萘和茚满衍生物及其作为5-ht拮抗剂的用途
RU2007135224A (ru) 2005-02-24 2009-03-27 Милленниум Фармасьютикалз, Инк. (Us) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
EP1924578B1 (fr) 2005-09-01 2013-11-06 Eli Lilly And Company 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES SUBSTITUEES PAR UN HETEROCYCLE A LIAISON 6-N EN TANT QU'AGONISTES DE RECEPTEUR 5-HT2C
GB0518783D0 (en) * 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
ES2625378T3 (es) * 2005-09-27 2017-07-19 Shionogi & Co., Ltd. Derivado de sulfonamida que tiene actividad antagonista del receptor de PGD2
CA2652501C (fr) 2006-05-26 2014-07-08 Toyama Chemical Co., Ltd. Nouveau compose heterocyclique et sel et intermediaire correspondants
AU2007258527A1 (en) 2006-06-12 2007-12-21 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
JP2009544721A (ja) * 2006-07-25 2009-12-17 サノフィ−アベンティス プロスタグランジンｄ２受容体アンタゴニストとしての２−フェニルインドール類
CL2007003693A1 (es) 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
JP5394487B2 (ja) 2008-07-15 2014-01-22 エフ．ホフマン−ラ ロシュ アーゲー アミノテトラヒドロインダゾロ酢酸
WO2010006944A1 (fr) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Acides aminotétrahydroindazoloacétiques
EP2321268A2 (fr) 2008-08-15 2011-05-18 F. Hoffmann-La Roche AG Bi-aryle aminotétralines
EP2321267A2 (fr) 2008-08-15 2011-05-18 F. Hoffmann-La Roche AG Monoaryle aminotétralines
JP5302398B2 (ja) 2008-08-15 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー 置換アミノテトラリン
CN102216249A (zh) 2008-11-17 2011-10-12 霍夫曼-拉罗奇有限公司 萘乙酸
CA2739725A1 (fr) 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Acides naphtylacetiques employes en tant qu'antagonistes ou agonistes partiels de crth2

Also Published As

Publication number Publication date
CR20110219A (es) 2011-08-24
ZA201102524B (en) 2014-09-25
NZ591914A (en) 2013-04-26
RU2011124150A (ru) 2012-12-27
ECSP11011057A (es) 2011-10-31
KR20110071121A (ko) 2011-06-28
CA2740863A1 (fr) 2010-05-20
CN102216265A (zh) 2011-10-12
HK1162461A1 (en) 2012-08-31
US8642629B2 (en) 2014-02-04
RU2539185C2 (ru) 2015-01-20
KR101322496B1 (ko) 2013-10-29
CO6351778A2 (es) 2011-12-20
EP2346819A1 (fr) 2011-07-27
PT2346819E (pt) 2013-05-10
DK2346819T3 (da) 2013-05-13
BRPI0921038A2 (pt) 2019-09-24
PE20110703A1 (es) 2011-10-13
IL212077A0 (en) 2011-06-30
JP2012508714A (ja) 2012-04-12
US20100125058A1 (en) 2010-05-20
EP2346819B1 (fr) 2013-04-10
CN102216265B (zh) 2014-04-30
TWI377197B (en) 2012-11-21
WO2010055004A1 (fr) 2010-05-20
HRP20130613T1 (en) 2013-07-31
AU2009315712A1 (en) 2010-05-20
RS52809B (sr) 2013-10-31
SG171734A1 (en) 2011-07-28
ES2408963T3 (es) 2013-06-24
TW201022207A (en) 2010-06-16
AR074352A1 (es) 2011-01-12
CY1114200T1 (el) 2016-08-31
PL2346819T3 (pl) 2013-09-30
MX2011005120A (es) 2011-05-30
JP5463365B2 (ja) 2014-04-09

Similar Documents

Publication Publication Date Title
MA32798B1 (fr) Acides naphtylacétiques
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
TN2009000138A1 (fr) Biaryl-ether-urees
MA31373B1 (fr) Composes amino-heterocycliques
MA35285B1 (fr) Indazoles
MA31339B1 (fr) Dérivés hétérobicycliques de pyrazole et méthodes d'utilisation
MA30406B1 (fr) Nouveaux composes
MA33295B1 (fr) Nouvelle formulation de diclofénac
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
EP2037739A4 (fr) Effecteurs allostériques positifs du récepteur m1 à base de quinolone à substitution benzyle
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar